drugset / Trial / NCT01549093

Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

NCT01549093

Phase 2 Unknown 90 enrolled Hunan Province Tumor Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Endostar with Gemcitabine-Carboplatin are more effective than Gemcitabine-Carboplatin alone in the treatment of Non-Small Cell Lung Cancer (NSCLC),and about Endostar ,Compared with intravenous, Continued vein-pumping maby is a more effective way.

Timeline

Start
2011-08
Primary completion
2016-07
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Endostar Protein / enzyme biologic 7.5 mg/m2 Intravenous
Comparator Carboplatin Small molecule 5 unknown Intravenous
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous